GLP1R and Parkinson disease: Recent epidemiological data on individuals with T2DM prescribed antidiabetic drugs indicates that those taking either dipeptidyl peptidase-4 (DPP-4) inhibitors or glucagon-like peptide-1 (GLP-1) receptor (R) agonists were 36 to 60% less likely to develop PD, as compared to those on other antidiabetic medications, such as metformin or sulfonylureas [8].